Nymox Pharmaceuticals (NASDAQ:NYMY) touts its own paid for research!

Nymox Pharmaceuticals (Nasdaq:NYMY) recently issued a press release touting they three analysts have issued buy recommendations. Nymox neglects to point out the three analyst firms are “paid for” and therefore are not what you might expect from a third party. The issue of paid for research continues to vex the investment world. By the way Nymox some of the reports are really old anyway and its time to update them.